for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Axsome Therapeutics Inc

AXSM.OQ

Latest Trade

92.08USD

Change

0.00(0.00%)

Volume

226,387

Today's Range

90.28

 - 

95.39

52 Week Range

7.64

 - 

109.94

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
92.08
Open
90.28
Volume
226,387
3M AVG Volume
26.96
Today's High
95.39
Today's Low
90.28
52 Week High
109.94
52 Week Low
7.64
Shares Out (MIL)
34.51
Market Cap (MIL)
3,341.35
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q4 2019 Axsome Therapeutics Inc Earnings Release

Latest Developments

More

Axsome Therapeutics Enters Into Exclusive License Agreement With Pfizer For Pfizer’s Reboxetine Clinical And Nonclinical Data And For New Phase 3 Esreboxetine Product Candidate

Axsome Therapeutics Says Axs-07 Achieves Co-Primary And Key Secondary Endpoints In Momentum Phase 3 Migraine Trial

Axsome Therapeutics Announces Pricing Of Public Offering Of $174 Mln Of Shares Of Common Stock

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Axsome Therapeutics Inc

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions, such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs), and chronic low back pain (CLBP), associated with type I, or mixed type I and type II Modic changes (MCs). Its product candidate, AXS 05, is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions, such as treatment resistant depression (TRD), and agitation in patients with Alzheimer's disease (AD).

Contact Info

200 Broadway 3rd Floor

+1.212.3323241

http://axsome.com/

Executive Leadership

Herriot Tabuteau

Chairman of the Board, President, Chief Executive Officer, Founder

Nick Pizzie

Chief Financial Officer

Mark Jacobson

Senior Vice President - Operations, Secretary

Cedric O'Gorman

Senior Vice President - Clinical Development and Medical Affairs

David C. Marek

Chief Commercial Officer

Key Stats

1.38 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-1.440

2017

-1.270

2018

-1.150

2019(E)

-1.771
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
457.44
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
289.58
LT Debt To Equity (MRQ)
280.07
Return on Investment (TTM)
-341.55
Return on Equity (TTM)
-175.46

Latest News

Latest News

Axsome shares surge 75% after depression drug reduces symptoms in late-stage study

Axsome Therapeutics Inc said on Monday its drug succeeded in reducing symptoms of major depressive disorder in a late-stage trial, taking the company a step closer to entering a multi-billion dollar market for depression treatments.

Axsome depression drug meets late-stage study goal

Axsome Therapeutics Inc said on Monday its drug succeeded in reducing symptoms of major depressive disorder in a late-stage trial, sending the company's share up 16% before the bell.

BRIEF-Axsome Therapeutics Reports Q1 Loss Per Share Of $0.19

* AXSOME THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Axsome Therapeutics Announces First Patient Enrolled In Phase 2 Clinical Trial Of AXS-05 In Smoking Cessation

* AXSOME THERAPEUTICS ANNOUNCES FIRST PATIENT ENROLLED IN PHASE 2 CLINICAL TRIAL OF AXS-05 IN SMOKING CESSATION Source text for Eikon: Further company coverage:

BRIEF-Axsome Therapeutics Appoints Nick Pizzie, Cpa, Mba, As Chief Financial Officer

* AXSOME THERAPEUTICS APPOINTS NICK PIZZIE, CPA, MBA, AS CHIEF FINANCIAL OFFICER

BRIEF-Axsome Therapeutics Reports Q4 Loss Per Share $0.31

* AXSOME THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Axsome Therapeutics Says Its CNS Disorder Candidate AXS-09 Met Main Goal Of Phase 1 Trial

* AXSOME THERAPEUTICS ANNOUNCES PRIMARY ENDPOINT MET IN PHASE 1 TRIAL OF NEXT GENERATION PRODUCT CANDIDATE AXS-09 CONTAINING CHIRALLY PURE ESBUPROPION AND DEXTROMETHORPHAN

BRIEF-Axsome Therapeutics Says AXS-02 Independent Data Monitoring Committee Recommends Continuation Of COAST-1 Trial

* AXSOME THERAPEUTICS ANNOUNCES AXS-02 INDEPENDENT DATA MONITORING COMMITTEE RECOMMENDS CONTINUATION OF COAST-1 TRIAL AND DISCONTINUATION OF CREATE-1 TRIAL

BRIEF-Sabby Management Reports A 5.52 Percent Passive Stake In Axsome Therapeutics

* SABBY MANAGEMENT, LLC REPORTS A 5.52 PERCENT PASSIVE STAKE IN AXSOME THERAPEUTICS INC AS OF DEC 1 - SEC FILING Source text : [http://bit.ly/2jNkBHB] Further company coverage:

BRIEF-Axsome Therapeutics Announces AXS-07 For The Treatment Of Migraine

* AXSOME THERAPEUTICS ANNOUNCES AXS-07 FOR THE TREATMENT OF MIGRAINE

BRIEF-Axsome Therapeutics reports Q3 loss per share $0.27

* Axsome Therapeutics reports third quarter 2017 financial results

BRIEF-Axsome enters agreement to sell up to $30 mln of shares of co's common stock

* Axsome Therapeutics-entered sales agreement to sell through leerink up to $30 million of shares of co's common stock,par value $0.0001/share-SEC filing Source text : (http://bit.ly/2gxqvzm) Further company coverage:

BRIEF-Axsome Therapeutics reports Q2 loss per share $0.30

* Axsome Therapeutics reports second quarter 2017 financial results

BRIEF-Axsome Therapeutics announces AXS-06 meets primary endpoint in phase 1 clinical trial

* Axsome Therapeutics announces AXS-06 (moseic meloxicam and esomeprazole) meets primary endpoint in phase 1 clinical trial

BRIEF-Axsome Therapeutics initiates Phase 2/3 trial of AXS-05 for Alzheimer’s disease agitation

* Axsome Therapeutics initiates Phase 2/3 trial of AXS-05 for Alzheimer’s disease agitation Source text for Eikon: Further company coverage:

BRIEF-Axsome appoints John Golubieski as CFO

* Axsome Therapeutics appoints John Golubieski as chief financial officer

BRIEF-Axsome Therapeutics Q1 loss per share $0.41

* Axsome therapeutics reports first quarter 2017 financial results

BRIEF-Axsome Therapeutics receives FDA fast track designation for axs-05 for alzheimer’s disease agitation

* Axsome therapeutics receives fda fast track designation for axs-05 for alzheimer’s disease agitation Source text for Eikon: Further company coverage:

BRIEF-Laurence Lytton reports 5.5 percent passive stake in Axsome Therapeutics

* Laurence Lytton reports 5.5 percent passive stake in Axsome Therapeutics Inc as of April 18 - sec filing Source text : http://bit.ly/2oQxSR9 Further company coverage:

BRIEF-Axsome Therapeutics reports pricing of public offering of common stock

* Axsome Therapeutics announces pricing of its public offering of common stock

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up